Cubist Systematic Strategies LLC Invests $1.93 Million in Haemonetics Co. (NYSE:HAE)

Cubist Systematic Strategies LLC purchased a new position in shares of Haemonetics Co. (NYSE:HAE - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 23,263 shares of the medical instruments supplier's stock, valued at approximately $1,925,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Capital Research Global Investors grew its holdings in shares of Haemonetics by 2.3% during the first quarter. Capital Research Global Investors now owns 6,674,751 shares of the medical instruments supplier's stock worth $569,690,000 after purchasing an additional 151,183 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Haemonetics by 0.5% in the fourth quarter. Vanguard Group Inc. now owns 5,406,309 shares of the medical instruments supplier's stock valued at $462,293,000 after acquiring an additional 25,451 shares during the last quarter. Wellington Management Group LLP boosted its holdings in Haemonetics by 3.2% in the fourth quarter. Wellington Management Group LLP now owns 3,268,083 shares of the medical instruments supplier's stock valued at $279,454,000 after acquiring an additional 101,029 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Haemonetics by 6.3% in the second quarter. Dimensional Fund Advisors LP now owns 978,735 shares of the medical instruments supplier's stock valued at $80,972,000 after acquiring an additional 57,665 shares during the last quarter. Finally, Thrivent Financial for Lutherans boosted its holdings in Haemonetics by 6,573.6% in the second quarter. Thrivent Financial for Lutherans now owns 849,350 shares of the medical instruments supplier's stock valued at $70,267,000 after acquiring an additional 836,623 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors.

Insider Activity at Haemonetics

In related news, insider Stewart W. Strong sold 4,312 shares of the stock in a transaction on Friday, July 26th. The stock was sold at an average price of $91.15, for a total value of $393,038.80. Following the completion of the sale, the insider now directly owns 18,196 shares of the company's stock, valued at approximately $1,658,565.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, EVP Anila Lingamneni sold 2,136 shares of the stock in a transaction on Thursday, July 11th. The stock was sold at an average price of $90.00, for a total value of $192,240.00. Following the completion of the sale, the executive vice president now directly owns 21,410 shares of the company's stock, valued at approximately $1,926,900. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Stewart W. Strong sold 4,312 shares of the firm's stock in a transaction on Friday, July 26th. The shares were sold at an average price of $91.15, for a total value of $393,038.80. Following the sale, the insider now directly owns 18,196 shares of the company's stock, valued at $1,658,565.40. The disclosure for this sale can be found here. 1.80% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on HAE. JMP Securities reiterated a "market outperform" rating and issued a $125.00 target price on shares of Haemonetics in a report on Tuesday, August 13th. Citigroup reduced their target price on Haemonetics from $94.00 to $85.00 and set a "neutral" rating on the stock in a report on Thursday, August 22nd. Barrington Research reiterated an "outperform" rating and issued a $108.00 target price on shares of Haemonetics in a report on Monday, September 23rd. CL King initiated coverage on Haemonetics in a report on Friday, September 13th. They set a "buy" rating and a $116.00 price target on the stock. Finally, BTIG Research initiated coverage on Haemonetics in a report on Tuesday, September 10th. They set a "buy" rating and a $112.00 price target on the stock. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $106.14.

Haemonetics Stock Down 1.7 %

Shares of NYSE:HAE traded down $1.38 during trading on Tuesday, reaching $79.00. 867,256 shares of the stock were exchanged, compared to its average volume of 545,916. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.76 and a quick ratio of 2.33. Haemonetics Co. has a 1-year low of $70.74 and a 1-year high of $97.97. The stock has a fifty day moving average of $78.73 and a two-hundred day moving average of $84.04. The firm has a market cap of $4.03 billion, a price-to-earnings ratio of 35.08, a price-to-earnings-growth ratio of 1.19 and a beta of 0.30.

Haemonetics (NYSE:HAE - Get Free Report) last issued its earnings results on Thursday, August 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, missing analysts' consensus estimates of $1.03 by ($0.01). Haemonetics had a return on equity of 21.86% and a net margin of 8.61%. The firm had revenue of $336.17 million for the quarter, compared to analyst estimates of $335.08 million. During the same period in the previous year, the company earned $1.05 earnings per share. Haemonetics's revenue for the quarter was up 8.0% compared to the same quarter last year. Research analysts anticipate that Haemonetics Co. will post 4.57 earnings per share for the current fiscal year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.